Anti-Nogo-A Antibodies enhance functional Recovery after Spinal Cord Injury in Humans; the Clinical Trials NISCI and SPROUT-1 (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR356.08 / Y5; Pres time: Nov 18, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; P1, P2 | "A recent Phase 2 clinical study with the anti-Nogo-A antibody NG101/ATI355 in acute spinal cord injury patients with cervical injuries (NISCI trial; NCT03935321; randomized, controlled trial with verum : placebo 2:1, 130 patients) has shown significantly improved upper extremity motor scores and SCIM-3 independence/quality of life scores in the patients with incomplete injuries (Weidner et al., 2025; Scheuren et al., 2026; Farner et al., 2026)...NISCI and SPROUT clinical teams: Swiss Paraplegic Center, Nottwil, Switzerland; University Hospital Balgrist, Zurich, Switzerland; REHAB Basel, Basel, Switzerland; Center for Paraplegiology, University of Heidelberg, Germany; BG Accident Clinic Murnau, Germany; Clinic for Paraplegia, Clinic Hohe Warte Bayreuth, Germany; BG Clinic Bergmannstrost Halle, Germany; Orthopedic Clinic Hessisch-Lichtenau, Germany; Center for Spinal Cord Injury, Trauma Center, Berlin, Germany; BG University Hospital Bergmannsheil,...
Clinical • CNS Disorders
|
|
M. E. SCHWAB1,3; S. MOESE3; B. ZÖRNER4; N. WEIDNER5; A. CURT2
|